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Zoom lectures are no fun. Unless there’s participation from EVERYONE.

Objectives
● Discuss approach to Syphilis testing and management in persons infected with HIV and HIV
negative patients
● Review strategies to improve ART adherence
● Review ART options and considerations for initiating and modifying ART and clinically
relevant Rx-Rx interactions
● Assess patients for HCV treatment and review simplified treatment strategies for patients with

chronic HCV infection

22 yo M presents with CC: I think I have syphilis
What else do
you want to
know?

HPI/PMH
Patient had been lost to care since 9/2019.
Labs at that time: HIV VL 124 , CD4 696 (38%).
Recently hospitalized 5/2020 and admitted to
rehab for schizophreniform d/o, crystal meth
use. Started on haldol, cogentin and sertraline
and currently in outpatient psychiatric Tx
Other history?

Prior Syphilis Hx:
7/2018: Syphilis EIA Ab+, RPR 1:64
(asymptomatic)
8/2018: RPR 1:512-> Treated with Bicillin IM x
1 dose
9/23/19: Syphilis EIA Ab+, RPR NR, Particle
Agglutination Reactive

Other history?
How would you treat him? (He has NKDA)

Follow up visit:
He reports adherence to ART and denies
missing any doses in the last month. You
decide to obtain repeat labs and follow up the
next week. Interim labs return:
HIV VL: 82,400 CD4 776 (36%)
RPR: 1:512
Does this change your treatment plan for
syphilis?
How would you address his HIV?

On exam you note mild bilateral upper extremity
postural tremor and dysmetria. His neuro
exam is otherwise unremarkable. He reports
tremor has been present since hospitalization in
May and preceded current rash.

Syphilis Natural history

Non-treponemal

Treponeme-Specific

Assays

RPR (Rapid Plasma Reagin)
VDRL (Venereal Disease
Research Laboratory)

TPPA (T Pallidum Particle
Agglutination)
EIA (T Pallidum Enzyme
Immunoassay)

Ab Detected

cardiolipin-cholesterol-lecithin ag

recombinant treponemal antigen

Sensitivity (False neg)

Poor in early infection
Long-standing w/ prolonged
latency

Earlier seroconversion
Remains + after treatment or
prolonged latency

Specificity (False +)

Lower- need to confirm + with
Treponemal test

Higher

Clinical Use:

Initial test in lower prevalence
areas (traditional seq)

Initial screening test in higher
prevalence areas (rev. seq)

Treatment response
Detecting re-infection in

Detection of early primary, old
latent infections

Reverse Sequence Testing Algorithm
In what scenarios would
negative testing warrant
treatment?
➔ Exposure within 90 days
to partner with confirmed
active infection
◆ retest 1,3 mo
➔ Skin lesion c/w primary
syphilis
◆ Retest at 2-4 weeks
if not treated

Treatment Algorithm

Syphilis Staging and Treatment:
Summary:
Primary, Secondary, early latent = 1 dose
Penicillin
Late/Unknown Latent: 3 weekly doses
Neurosyphilis: 10-14 days IV

Treat with Penicillin whenever possible. Only
agent with good data in pregnancy, persons with
HIV or neurosyphilis

Monitoring Response to Treatment:
Follow up testing:
●

●
●

Obtain repeat RPR w/ titer at 6&12
months
Consider 3,6,9,12 &24 if HIV+
Should see 2 dilution (4-fold) decrease in
titer

How to address possible Treatment Failure:
●
●
●
●

Rule out unrecognized HIV infection
Evaluate for re-infection (by symptoms or
exposures)
Assess adherence if Tx’d w/ oral regimen
Rule out neuro, ocular, otosyphilis

When to Worry about Treatment Failure:
●
●

●

Persistent Si/sx after Tx
Sustained 2+ week rise in titer (4 fold) s/p
Tx
Failure of RPR to decrease 4 fold in 6-12
mo

Retreat with 3 weekly doses of benzathine
Penicillin G if no evidence of CNS infection

HIV and Syphilis:
● Interpretation of treponemal and nontreponemal testing the same
● Stage-based treatment is the same for those who are HIV negative
○

Penicillin alternatives not well studied in HIV+ individuals

● May have higher rates of serologic failure or “high serofast” state
● Higher risk for neurological complications in early (primary/secondary)
infection
● CSF abnormalities associated with CD4 <350, RPR > 1:32
○

No clear indication for LP in the absence of neuro signs/sx

Is anyone paying attention?
Syphilis Kahoots!

HIV Treatment
Prior HIV labs and treatment history:
He reports adherence to ART and denies
missing any doses in the last month. You
decide to obtain repeat labs and follow up the
next week. Interim labs return:
HIV VL: 82,400
CD4 776 (36%)

HIV Dx 7/2018: VL: 402,626, CD4 698 (26%)
Started on B/TAF/FTC (lost to care),
8/27/19: VL 21,159 (reported 2 week Tx lapse)
HIV genotype: NRTI: no RAMs, NNRTI:
E138A, PI: no RAMs, INSTI: No RAMs
9/23/19: VL 124 CD4 696 (38%)
How can we promote ART adherence?
How would you address his viremia?

Linkage & Retention:

Adherence Strategies:
➔ • Regularly assess adherence to ART and appointments.
◆ Engage patients with a constructive,collaborative, nonjudgmental, and problem-solving approach
➔ Elicit an individual’s barriers to adherence:
◆ personal barriers (e.g., substance use, housing instability, stigma, lack of transportation)
◆ clinic barriers (e.g., limited clinic hours, processes that make it more difficult to obtain prescriptions or
schedule appointments)
◆ system barriers (e.g. copays/assistance,PAT ,other Rx coverage/refill processes)
➔ Tailor ART to improve adherence:
◆ Involve patient in treatment decisions/ART selection
◆ simplify dosing or reduce side effects
◆ Choose regimens without food requirements
◆ Choose ART regimen with high genetic barrier to resistance (dolutegravir (bictegravir), boosted-darunavir
◆ Consider out of pocket costs/copays
➔ Link patients to counseling to overcome stigma, substance use, or depression
➔ Multidisciplinary approaches and time to understand and address barriers are needed with help of social work and
case management when available

HIV Treatment
Prior HIV labs and treatment history:
He reports adherence to ART and denies
missing any doses in the last month. You
decide to obtain repeat labs and follow up the
next week. Interim labs return:
HIV VL: 82,400
CD4 776 (36%)

HIV Dx 7/2018: VL: 402,626, CD4 698 (26%)
Started on B/TAF/FTC (lost to care),
8/27/19: VL 21,159 (reported 2 week Tx lapse)
HIV genotype: NRTI: no RAMs, NNRTI:
E138A, PI: no RAMs, INSTI: No RAMs
9/23/19: VL 124 CD4 696 (38%)

How would you address his viremia?

ARV Viremia ?s

Terminology Review
Virologic suppression: A confirmed HIV RNA level below level of detection
Virologic failure: The inability to achieve or maintain suppression of viral replication to an

HIV RNA level <200 copies/mL
Incomplete virologic response: Two HIV RNA levels ≥200 copies/mL after 24 weeks on an
ARV regimen w/o documented suppression
Virologic rebound: Confirmed HIV RNA ≥200 copies/mL after virologic suppression
Virologic blip: After virologic suppression, an isolated detectable HIV RNA level that is

followed by a return to virologic suppression
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.

Department of Health and Human Services

Potential Causes of Viremia:

● Suboptimal adherence
● Viral blip
● Drug resistance:
■ Inherited/Transmitted
■ Acquired
● Suboptimal adherence
● Rx-Rx or Food-Rx interactions

Addressing Detectable Viral Load: Clinical Situations
●

●

●

●

HIV RNA above the LLOD and <200 copies/mL. Confirm VL and assess adherence, drug-drug and drug-food
interactions.
a.

Viral blip does not require change in treatment(AII)

b.

Persistent viremia <200 copies/mL- risk of resistance low but requires closer monitoring (AIII)

HIV RNA ≥200 and <1,000 copies/mL. Confirm VL and assess as per above

a.

Persistently >200 copies/mL- higher risk of resistance

b.

If confirmatory VL > 1000 copies/mL- obtain resistance testing (consider if >500)

HIV RNA >1,000 copies/mL and no drug resistance identified.
a.

Patient is likely not taking meds - confirm timing of test relative to patient stopping meds

b.

If the current regimen is well tolerated- restart old regimen- repeat VL 2-4 weeks after restarting and if VL >500
get resistance testing

HIV RNA >1,000 copies/mL and drug resistance identified.
a.

Change ART regimen

Case 2: JW 51yo M presents for f/u of HIV and
chronic conditions
He takes the following medications:
HIV: Elvitegravir/cobicistat/tenofovir AF/Emtricitabine (Genvoya)
Mod-persistant Asthma/Allergy: albuterol HFA, montelukast 10mg, fluticasone
furoate/vilanterol (Breo) 200mcg/25mcg, Fluticasone prop. nasal

DM2: glipizide XL 20mg daily, Metformin XR 750mg BID, januvia 100mg daily
HTN/HL: lisinopril 10mg daily, chlorthalidone 25mg daily atorvastatin 40mg daily
GERD: Omeprazole 40mg daily

Case 2: JW 51yo M presents for f/u of HIV and
chronic conditions
He obtained the Following labs prior to his visit:
HIV VL <40, CD4 1165 (44%)
HbA1c: 9.2%
Cr: 1.4 (eGFR 45)
LDL 51, TG 81, HDL 59 (ASCVD 20%)
He is reluctant to start insulin or other injectable medications for DM. How can we
optimize his regimen?

Moore Kahoots!

ARVs and Glucocorticoids
https://www.hivdruginteractions.org/drug_queries/472812/drug_query_interactions/table_view

Medication Interactions

http://www.hiv-druginteractions.org

Statins and PK inhibitors

● Most PIs (and boosted INSTI) inhibit the metabolism of most statins
● Increased risk of toxicity
● Simvastatin and Lovastatin have the most interactions

● Fluvastatin and Pitavastatin have a safer profile
● Atorvastatin had the most data with Darunavir/r - need to dose adjust

ARV and GERD Treatments

Food-Drug Interactions
● No Food Requirement:
○ Bictegravir,Dolutegravir or
Raltegravir- based regimens
(INSTI)
● Take with Food:
○ Atazanavir/r, Darunavir/r
(PI)
○ Elvitegravir based regimen
(INSTI)

○ Rilpivirine (NNRTI)

● Take without food:
○ Efavirenz (NNRTI)
Note on Rilpivirine (RPV):
● Requires acid for adequate
absorption

○ Requires >390 kcal meal
○

Contraindicated with PPIs

○ Separate H2 or antacids

HCV Case- RS
63yo M Hx of chronic HCV, Seizure d/o, Latent
TB (untreated), DM2, GERD, HTN, CKD and
remote CVA presents for routine follow up.

Hx of chronic HCV first Dx’d in 2015. Tx naive.
Remote hx of IDU.
Current meds: Amlodipine 5 mg, keppra 1500
mg TID. Valproic acid 750 MG BID,
Atorvastatin 40mg, Pantoprazole 40mg daily

Labs/Studies:
HCV PCR: 5,290,000 copies/mL
Genotype: 1b, NS5a resistance not predicted
HIV Ab/Ag: NR
HbsAg: NR, HbsAb: NR, HbcAb: Reactive

HepA IgG,IgM: NR
Hgb 11.9, Plt 295

How would you evaluate him for treatment?
AST: 39, ALT 34, ALP 57, Tbil 0.4, Alb 4.3

Elastography: Median liver stiffness 6.59 kPa, mod risk
of clinically significant fibrosis (F2-F3), hepatic steatosis

Steps before treatment HCV Ab+ patients:
1) Are they infected? Get HCV PCR

2) Have they been treated before?

5)

Is there evidence of HCC? Eval with US

6)

Medication reconciliation & review interactions:

a)
b)
c)

3) Do they have Cirrhosis?:
a)

***Calculate FIB-4 score. >3.25 OR

b)

***Transient elastography indicating cirrhosis (eg,
FibroScan stiffness >12.5 kPa)

c)

Noninvasive serologic tests above cutoffs (eg,
FibroSure, Enhanced Liver Fibrosis Test, etc)

d)

Clinical evidence of cirrhosis (eg, liver nodularity
and/or splenomegaly on imaging, platelet count
<150,000/mm3)

e)

Prior liver biopsy showing cirrhosis

4) If yes, is it decompensated?:
a)

Calculate CTP score: ≥ 7 or ascites,
encephalopathy, Tbili≥2, INR≥1.7, Albumin <3.5 ->
If yes then refer

AASLD/IDSA guidance
Liverpool drug interaction checker.
Pretreatment laboratory testing:

7)

Do they have HIV? Order Ab/Ag test

8)

Do they have chronic hep B? Order HbSAg

9)

Get additional Labs (if needed)

a)
b)
c)

Complete blood count (CBC)
Hepatic function panel
eGFR (Cr)

10) Are they or can they get pregnant? Pregnancy Test &
counsel

Treatment of HCV
1)

Glecaprevir (300 mg) / pibrentasvir (120 mg) (Mavyret) for 8
weeks

2)

a)

Needs to be taken with food

b)

PI raises potential for Rx-Rx interactions

c)

3 tablets daily

Sofosbuvir (400 mg) / velpatasvir (100 mg) (Epclusa) for 12

Treatment monitoring:

➔
➔
➔
➔

Assess adherence and treatment side effects
Monitor hypoglycemia in diabetic patients
INR if on warfarin
Cirrhosis: consider LFTs in patients

weeks

a)

In compensated cirrhosis need NS5A resistance

Post-treatment evaluation:

testing for genotype 3
b)

Single tablet

Be mindful of Rx interactions:
➔

Statins

➔

PPI, H2RA, Antacids

➔

Anticoagulants

➔

Antiepileptics

➔

Hypoglycemic drugs

➔ Confirm SVR-12 with HCV PCR 12 weeks
after treatment along with LFTs
➔ Assess reinfection risk
➔ Limit/avoid ETOH
➔ Cirrhosis: HCC screening w/ US q6mo,
variceal screening with EGD q2-3yr

HCV Kahoots

Resources
DHHS: https://aidsinfo.nih.gov/
IAS-USA: https://www.iasusa.org/
Ward 86 :https://hiv.ucsf.edu/education/recommendations.html
Liverpool HIV interactions: http://www.hiv-druginteractions.org/
Liverpool HCV interactions: https://www.hep-druginteractions.org/

HIV and Aging: http://hiv-age.org/
Stanford University HIV Resistance Database: http://hivdb.stanford.edu
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